Related Experiment Videos
Left ventricular hypertrophy: should it be reduced?
F H Messerli1, F Soria, D Aristizabal
1Department of Internal Medicine, Ochsner Clinic, New Orleans, LA 70121.
Insights
Left ventricular hypertrophy (LVH) is a heart condition linked to high blood pressure. ACE inhibitors effectively reduce LVH, improving heart function, but their impact on reducing cardiovascular death risk is still under investigation.
Area of Science:
- Cardiology
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) is a cardiac adaptation to hypertension.
- LVH is an independent risk factor for cardiovascular events like heart attack and sudden death.
- Pathophysiological consequences include impaired filling, contractility, arrhythmias, and ischemia.
Purpose of the Study:
- To evaluate the impact of antihypertensive therapies on LVH.
- To assess the efficacy of Angiotensin-Converting Enzyme (ACE) inhibition in reducing LVH.
- To determine if LVH reduction improves associated pathophysiological sequelae.
Main Methods:
- Review of recent clinical studies on LVH and antihypertensive treatments.
- Analysis of the effects of different drug classes, particularly ACE inhibitors.
- Evaluation of changes in left ventricular function and associated risks.
Main Results:
- LVH is a significant predictor of cardiovascular morbidity and mortality.
- ACE inhibition is a potent monotherapy for reducing LVH.
- Reduction in LVH improves cardiac function and associated pathophysiological issues.
Conclusions:
- Antihypertensive therapy, especially ACE inhibition, can reduce LVH and improve cardiac function.
- It is currently unknown if LVH reduction translates to decreased cardiovascular mortality.
- Further research is needed to confirm the long-term benefits of LVH reversal on sudden death and heart failure risk.
Abstract:
Left ventricular hypertrophy (LVH) is a structural adaptation of the heart to sustained hypertension, serving to normalize increased wall stress. Recent clinical studies have indicated that LVH is a powerful pressure-independent risk factor for cardiovascular morbidity and mortality, particularly sudden death, acute myocardial infarction, and congestive failure. The pathophysiologic sequelae of LVH consist of reduced ventricular filling and contractility, ventricular dysrhythmias, and diminished coronary reserve or myocardial ischemia. LVH can be reduced by antihypertensive therapy, although not all drugs are equipotent in this regard. Angiotensin-converting enzyme (ACE) inhibition seems to be the most powerful monotherapeutic modality for reducing LVH. Recent studies have shown that such a reduction also improves the pathophysiologic sequelae of LVH and maintains left ventricular pump function. Although the reversal of these pathophysiologic events is encouraging, it remains unknown whether reducing LVH will ultimately decrease the excessive risk of sudden death, acute myocardial infarction, and congestive heart failure that has been associated with this disorder independently of arterial pressure.